Injunctive relief Even ahead of the spinoff, analysts had been predicting doom and gloom for AbbVie once its blockbuster anti-inflammatory drug Humira faces biosimilar competition in the United States. At more than 60% of total revenue, there's a lot to be concerned about. When the company reported third-quarter earnings, the headline numbers were encouraging, but what stoked the market was assurance from CEO Rick Gonzalez that an army of patent lawyers is prepared to secure Humira's future. In the U.S., which generates more than 60% of Humira sales, AbbVie's main composition-of-matter patent expires at the end of next year. That's the bad news. But AbbVie's legal department has been working around the clock since the spinoff. The company now claims a whopping 75 patents related to Humira. This list includes 16 that are indication specific, the first of which don't expire until 2022.